‘Agglutination and flocculation’ of stem cells collected by apheresis due to cryofibrinogen

Ma, Siegenthaler; Dh, Vu; Ebnöther, Monika; Ketterer, Nicolas; Lüthi, François; Schmid, P.; Bargetzi, Mario; Gasparini, Danielle; Tissot, Jean‐Daniel

doi:10.1038/sj.bmt.1704420

Cited by 11 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of monoclonal gammopathies [45,46] and characterization of cryoproteins [47][48][49] using 2-DE has been shown to be useful in selected difficult clinical situations. Using 2-DE analyses and MS, we also recently identified a new peptide, called hSpa or CD5L [50].…”

Section: Clinical Applications -Biomarker Identificationmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in blood‐related proteomics

et al. 2005

View full text Add to dashboard Cite

Service régional vaudois de transfusion sanguine, Lausanne, SwitzerlandBlood is divided in two compartments, namely, plasma and cells. The latter contain red blood cells, leukocytes, and platelets. From a descriptive medical discipline, hematology has evolved towards a pioneering discipline where molecular biology has permitted the development of prognostic and diagnostic indicators for disease. The recent advance in MS and protein separation now allows similar progress in the analysis of proteins. Proteomics offers great promise for the study of proteins in plasma/serum, indeed a number of proteomics databases for plasma/ serum have been established. This is a very complex body fluid containing lipids, carbohydrates, amino acids, vitamins, nucleic acids, hormones, and proteins. About 1500 different proteins have recently been identified, and a number of potential new markers of diseases have been characterized. Here, examples of the enormous promise of plasma/serum proteomic analysis for diagnostic/prognostic markers and information on disease mechanism are given. Within the blood are also a large number of different blood cell types that potentially hold similar information. Proteomics of red blood cells, until now, has not improved our knowledge of these cells, in contrast to the major progresses achieved while studying platelets and leukocytes. In the future, proteomics will change several aspects of hematology.

show abstract

Section: Clinical Applications -Biomarker Identificationmentioning

confidence: 99%

“…Most frequently, the precipitates contain Igs and are therefore called cryoglobulins (reviewed in [46] [46]. In addition, proteins such as albumin [48] and fibrinogen [49] can also cryoprecipitate.…”

Section: Cryoproteinsmentioning

confidence: 99%

Recent advances in blood‐related proteomics

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Our investigation revealed that compared to 2006, less ACD-A was used in products collected during 2007 and 2008. Although PBSC clotting can result from accumulation of different causes including plasma cryofibrinogens [9] or specific donor-related factors, insufficient anticoagulant was a reasonable contributing factor in these events. The ACD-A percentage in the two products described here was lower than 7%, which is much less than the average anticoagulant content for all three years.…”

Section: Discussionmentioning

confidence: 97%

Postthaw clotting of peripheral blood stem cell products due to insufficient anticoagulant

Reich-Slotky

Patel

Dael

et al. 2009

J of Clinical Apheresis

View full text Add to dashboard Cite

The amount of acid citrate dextrose formula A (ACD-A), which is a commonly used anticoagulant in leukopheresis, has to ensure both the safety of the donor and guarantee the integrity of the peripheral blood stem cell (PBSC) product until its transplant. Two recent consecutive cases of postthaw PBSC product clotting initiated a look-back investigation of the ACD-A percentage in leukopheresis products collected in our facility. The data indicated a significant difference between the average amount of ACD-A in prefreezing products collected during 2006 (11.4%) and in products collected during 2007 and 2008 (8.8% and 8.7%, respectively). These findings and the fact that the two clotted products had less than 7% ACD-A indicated that insufficient amount of anticoagulant might contribute to their clotting. This investigation prompted us to modify our collection and thawing procedures to prevent similar events in the future.

show abstract

“…Similar findings have been reported with autologous PBPCs and have been associated with cryofibrinogens. 2 Cryofibrinogens were not measured in our donor, but a blood sample examined after 2 days of refrigeration had no visible clumps. Based on our experience, we recommend the use of 5 percent albumin for processing of PBPCs if clumping is noticed when plasma is used.…”

mentioning

confidence: 86%

“…Agglutination or clumping of hematopoietic progenitor cells has been known as a possible complication of the dimethyl sulfoxide (DMSO) cryopreservation process. 1,2 We encountered a 64‐year‐old man with Type 2 diabetes, coronary artery disease, status post–coronary artery bypass graft surgery, peripheral neuropathy, and a chronic ulcer of his foot, who donated peripheral blood progenitor cells (PBPCs) for his HLA‐matched sibling. His apheresis collections were uneventful.…”

mentioning

confidence: 99%

Clumping in an apheresis‐collected peripheral blood progenitor cell product

et al. 2008

View full text Add to dashboard Cite

Agglutination or clumping of hematopoietic progenitor cells has been known as a possible complication of the dimethyl sulfoxide (DMSO) cryopreservation process. 1,2 We encountered a 64-year-old man with Type 2 diabetes, coronary artery disease, status post-coronary artery bypass graft surgery, peripheral neuropathy, and a chronic ulcer of his foot, who donated peripheral blood progenitor cells (PBPCs) for his HLA-matched sibling. His apheresis collections were uneventful. During the processing, clumping was noted in the product after mixing with autologous plasma and DMSO (see figure, left). Subsequently, it was noted that the cryopreservative solution itself (20% plasma and 20% DMSO in Normosol-R and 5% dextrose; Hospira, Lake Forest, IL) also had clumping (see figure, middle). A Wright-Giemsa stain of the clumps revealed fibrinous clots with trapped mononuclear cells (see figure, right). When the product was processed with 5 percent albumin and DMSO, no clumping was noted. No products were infused due to the death of the recipient. One product bag processed with albumin was thawed with no observed clumping. Similar findings have been reported with autologous PBPCs and have been associated with cryofibrinogens. 2 Cryofibrinogens were not measured in our donor, but a blood sample examined after 2 days of refrigeration had no visible clumps. Based on our experience, we recommend the use of 5 percent albumin for processing of PBPCs if clumping is noticed when plasma is used. REFERENCES1. Weiner RS, Tobias JS, Yankee RA. The processing of human bone marrow for cryopreservation and reinfusion. Biomedicine 1976; 24:226-31.

show abstract

‘Agglutination and flocculation’ of stem cells collected by apheresis due to cryofibrinogen

Cited by 11 publications

References 13 publications

Recent advances in blood‐related proteomics

Recent advances in blood‐related proteomics

Postthaw clotting of peripheral blood stem cell products due to insufficient anticoagulant

Clumping in an apheresis‐collected peripheral blood progenitor cell product

Contact Info

Product

Resources

About